Here are the Form 4 insider transactions from Salarius Pharmaceuticals, Inc. (SLRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SLRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLRX filings page.
Salarius Pharmaceuticals, Inc. (SLRX) director reports stock purchase. A trust associated with director Arnold C. Hanish bought 5,000 shares of Salarius common stock on 11/20/2025 at a weighted average price of $0.7481 per share. These shares were acquired in multiple trades at prices ranging from $0.7437 to $0.75. After this transaction, the trust beneficially owned 5,015 shares of Salarius common stock, reported as indirect ownership on the Form 4.
Salarius Pharmaceuticals (SLRX) reported an insider stock purchase by its Executive VP Finance and CFO, Mark J. Rosenblum. On 11/20/2025, he bought 20,000 shares of Salarius common stock at a price of $0.80 per share in an open-market transaction. After this purchase, he beneficially owns 20,177 shares of common stock, which includes 20 shares of unvested restricted stock granted on January 3, 2023. The reported post-transaction share amount reflects prior reverse stock splits that were effective on June 16, 2024 and August 17, 2025.